Clinical trials
Completed Phase 2 Carcinoma, Transitional Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 6 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3 |
| RemeGen Co., Ltd. | 3 |
| Achieve Life Sciences | 2 |
| Asan Medical Center | 2 |
| Bristol-Myers Squibb | 2 |
| Matthew Galsky | 2 |
| National Taiwan University Hospital | 2 |
| Spanish Oncology Genito-Urinary Group | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 66 |
| Urinary Bladder Neoplasms | 32 |
| Ureteral Neoplasms | 9 |
| Neoplasm Metastasis | 6 |
| Urethral Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Neoplasms | 4 |
| Urologic Neoplasms | 4 |
| Kidney Neoplasms | 3 |
| Acrocephalosyndactylia | 2 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.